Meeting
2013 ASCO Annual Meeting
Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM).
Authors
Ryo Nishikawa
Saitama Medical University International Medical Center, Saitama, Japan
Ryo Nishikawa , Frank Saran , Warren Mason , Wolfgang Wick , Timothy Francis Cloughesy , Roger Henriksson , Magalie Hilton , Josep Garcia , Tobias Vogt , Celine Pallaud , Oliver L. Chinot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00943826
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2023^)
DOI
10.1200/jco.2013.31.15_suppl.2023
Abstract #
2023^
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).
First Author: Martha Nowosielski
Poster
2014 ASCO Annual Meeting
Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB).
First Author: Wolfgang Wick
Poster
2011 ASCO Annual Meeting
AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
First Author: O. L. Chinot
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
First Author: Howard Colman